作者
Nathaniel J Rhodes, Atheer Dairem, William J Moore, Anooj Shah, Michael J Postelnick, Melissa E Badowski, Sarah M Michienzi, Jaime L Borkowski, Radhika S Polisetty, Karen Fong, Emily S Spivak, James R Beardsley, Cory M Hale, Andrea M Pallotta, Pavithra Srinivas, Lucas T Schulz
发表日期
2021/4/1
期刊
American Journal of Health-System Pharmacy
卷号
78
期号
7
页码范围
568-577
出版商
Oxford University Press
简介
Key points
In a multicenter point-prevalence study, we found that the rate of supportive care was high; among those receiving COVID-19 drug therapies, adverse reactions occurred in 12% of patients.
Purpose
There are currently no FDA-approved medications for the treatment of coronavirus disease 2019 (COVID-19). At the onset of the pandemic, off-label medication use was supported by limited or no clinical data. We sought to characterize experimental COVID-19 therapies and identify safety signals during this period.
Methods
We conducted a noninterventional, multicenter, point prevalence study of patients hospitalized with suspected/confirmed COVID-19. Clinical and treatment characteristics within a 24-hour window were evaluated in a random sample of up to 30 patients per site. The primary objective was to describe COVID-19–targeted therapies …
学术搜索中的文章
NJ Rhodes, A Dairem, WJ Moore, A Shah… - American Journal of Health-System Pharmacy, 2021